ClinicalTrials.gg
CompletedNCT06592339Updated Sep 19, 2024

A Study of MK-0616 in Healthy Adult Participants (MK-0616-009)

A Phase 1 interventional study of MK-0616 in Hypercholesterolemia, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2022, 3 years 10 months ago, and no results have been posted to the registry.
  • Registered 1 year 10 months after the study started (first participant enrolled Oct 2022, registered Sep 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies in Hypercholesterolemia by Merck & Co., Inc — 1 open to participants now, 3 under way, 3 of them phase 3. Hypercholesterolemia · Merck & Co., Inc.

Enrollment
27th of 27
24 · median 500
Started
2022
with 2 others
Phase 1
6 of 29
none open now
Registered
27th of 29
by date

Among the 29 studies in Hypercholesterolemia by Merck & Co., Inc, this one is the 27th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2022, is one of 6 in phase 1, and was the 27th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 29 studies in Hypercholesterolemia by Merck & Co., Inc is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Hypercholesterolemia by Merck & Co., Inc, or all of them as a file.
02

Study summary

The goal of the study is to learn what happens to levels of MK-0616 in the blood when MK-0616 is given in different forms. Researchers believe that there is no effect on a healthy person's body if MK-0616 is given in different forms.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key inclusion criteria include but are not limited to the following:

  • Is in good health before randomization
  • Has a (BMI) ≥18 and ≤32 kg/m\^2, inclusive

Exclusion criteria

Exclusion Criteria:

The key exclusion criteria include but are not limited to the following:

  • Has a history of endocrine, GI, cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases
  • Has a history of cancer with pre-specified exceptions (adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix or other that have been successfully treated with appropriate follow up and therefore unlikely to recur for the duration of the study, per protocol guidelines)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Sequence 1: MK-0616 Reference capsule→MK-0616 Formulation 1 (F1)→MK-0616 Formulation 2 (F2)

    Period 1: Participants receive MK-0616 reference capsule single dose on Day 1 orally (Period 1 = 15 days). Period 2: Participants receive MK-0616 F1 single dose on Day 1 orally (Period 2 = 15 days). Period 3: Participants receive MK-0616 F2 single dose on Day 1 orally (Period 3 = 15 days). A washout period of 14 days will separate Period 1, Period 2 and Period 3.

    Drug: MK-0616

  • Experimental
    Sequence 2: MK-0616 Reference capsule→MK-0616 F2→MK-0616 F1

    Period 1: Participants receive MK-0616 reference capsule single dose on Day 1 orally (Period 1 = 15 days). Period 2: Participants receive MK-0616 F2 single dose on Day 1 orally (Period 2 = 15 days). Period 3: Participants receive MK-0616 F1 single dose on Day 1 orally (Period 3 = 15 days). A washout period of 14 days will separate Period 1, Period 2 and Period 3.

    Drug: MK-0616

  • Experimental
    Sequence 3: MK-0616 F1→MK-0616 Reference capsule→MK-0616 F2

    Period 1: Participants receive MK-0616 F1 single dose on Day 1 orally (Period 1 = 15 days). Period 2: Participants receive MK-0616 reference capsule single dose on Day 1 orally (Period 2 = 15 days). Period 3: Participants receive MK-0616 F2 single dose on Day 1 orally (Period 3 = 15 days). A washout period of 14 days will separate Period 1, Period 2 and Period 3.

    Drug: MK-0616

  • Experimental
    Sequence 4: MK-0616 F1→MK-0616 F2→MK-0616 Reference capsule

    Period 1: Participants receive MK-0616 F1 single dose on Day 1 orally (Period 1 = 15 days). Period 2: Participants receive MK-0616 F2 single dose on Day 1 orally (Period 2 = 15 days). Period 3: Participants receive MK-0616 reference capsule single dose on Day 1 orally (Period 3 = 15 days). A washout period of 14 days will separate Period 1, Period 2 and Period 3.

    Drug: MK-0616

  • Experimental
    Sequence 5: MK-0616 F2→MK-0616 Reference capsule →MK-0616 F1

    Period 1: Participants receive MK-0616 F2 single dose on Day 1 orally (Period 1 = 15 days). Period 2: Participants receive MK-0616 reference capsule single dose on Day 1 orally (Period 2 = 15 days). Period 3: Participants receive MK-0616 F1 single dose on Day 1 orally (Period 3 = 15 days). A washout period of 14 days will separate Period 1, Period 2 and Period 3.

    Drug: MK-0616

  • Experimental
    Sequence 6: MK-0616 F2→MK-0616 F1→MK-0616 Reference capsule

    Period 1: Participants receive MK-0616 F2 single dose on Day 1 orally (Period 1 = 15 days). Period 2: Participants receive MK-0616 F1 single dose on Day 1 orally (Period 2 = 15 days). Period 3: Participants receive MK-0616 reference capsule single dose on Day 1 orally (Period 3 = 15 days). A washout period of 14 days will separate Period 1, Period 2 and Period 3.

    Drug: MK-0616

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration-Time Curve from Time 0 to Infinity (AUC0-Inf) of MK-0616

    Blood samples will be collected to determine the AUC0-inf of MK-0616.

    Time frame: Predose and at designated timepoints up to 168 hours postdose

  2. Area Under the Concentration-Time Curve from Time 0 to 24 hours (AUC0-24hr) of MK-0616

    Blood samples will be collected to determine the AUC0-24 of MK-0616.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  3. Area Under the Concentration-Time Curve from Time 0 to Last (AUC0-Last) of MK-0616

    Blood samples will be collected to determine the AUC0-last of MK-0616.

    Time frame: Predose and at designated timepoints up to 168 hours postdose

  4. Maximum Plasma Concentration (Cmax) of MK-0616

    Blood samples will be collected to determine the Cmax of MK-0616.

    Time frame: Predose and at designated timepoints up to 168 hours postdose

  5. Maximum Plasma Concentration (C24) of MK-0616

    Blood samples will be collected to determine the C24 of MK-0616.

    Time frame: Predose and at designated timepoints up to 24 hours postdose

  6. Apparent Terminal Half-life (t1/2) of MK-0616

    Blood samples will be collected to determine the apparent t1/2 of MK-0616.

    Time frame: Predose and at designated timepoints up to 168 hours postdose

  7. Time to Maximum Plasma Concentration (Tmax) of MK-0616

    Blood samples will be collected at pre-specified timepoints to determine the Tmax of MK-0616.

    Time frame: Predose and at designated timepoints up to 168 hours postdose

Secondary outcomes

  1. Number of Participants Who Experience an Adverse Event (AE)

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who experience an AE will be reported.

    Time frame: Up to approximately 2 months

  2. Number of Participants Who Discontinue Study Due to an AE

    An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants who discontinue study due to an AE will be reported.

    Time frame: Up to approximately 2 months

07

Study locations

1 site
  • QPS-MRA, LLC-Early Phase
    South Miami, Florida 33143, United States
08

References and documents

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2022 to primary completion in Dec 2022, 2 months.

Of 41 industry-sponsored phase 1 interventional studies under Hypercholesterolemia, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 2 months is below that.

Counting every sponsor, half of 46 studies reached it within 7 months; a quarter within 2 and three quarters within 10.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2024
First posted
Sep 19, 2024
StartActual
Oct 25, 2022
Primary completionActual
Dec 29, 2022
CompletionActual
Dec 29, 2022
Last update
Sep 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06592339
Responsible party
Sponsor
First posted
Sep 19, 2024
Start date
Oct 25, 2022
Primary completion
Dec 29, 2022
Completion
Dec 29, 2022
Last update
Sep 19, 2024

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: MK-0616

Start the discussion